Phase I study of piritrexim and gemcitabine in patients with advanced solid tumors

Michael Huie, Michael A Carducci, Glenn Liu, George Wilding, Rebecca Marnocha, Miguel Izquierda, James Thomas

Research output: Contribution to journalArticle

Abstract

Objectives: In this phase I study, the combination of piritrexim and gemcitabine was given to establish the maximum tolerated dose and the recommended phase II dose, and to determine a toxicity and efficacy profile. Methods: Fifty-two patients with normal and impaired renal function were enrolled on this phase I study. The starting dose was piritrexim 10 mg 3 times daily (5 days of the week for 3 weeks and 1 week off each 28-day cycle) and gemcitabine 1000 mg/m2 on days 1, 8, and 15. The piritrexim was escalated in a stepwise fashion with this dose of gemcitabine and then with gemcitabine 1000 mg/m2 for days 1 and 15. Results: The recommended phase II dose of this combination was felt to be piritrexim 50 mg/day (10 mg every morning, 20 mg every noon, and 20 mg every evening) with gemcitabine 1000 mg/m2 on days 1, 8, and 15, and piritrexim 75 mg/day (25 mg thrice daily) with gemcitabine 1000 mg/m2 on days 1 and 15. Neutropenia and thrombocytopenia were the most often reported toxicity. Dose-limiting toxicity was thrombocytopenia in both groups. The number of renal-impaired patients enrolled was too small to establish a maximum tolerated dose for this group (piritrexim became unavailable), but the combination was tolerated in the patients with impaired renal dysfunction. There was 1 complete response, 1 partial response, and 1 minimal response. Conclusion: The combination of piritrexim and gemcitabine was determined to be tolerable in heavily pretreated patients for use in solid tumors.

Original languageEnglish (US)
Pages (from-to)613-617
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume28
Issue number6
DOIs
StatePublished - Dec 2005

Fingerprint

gemcitabine
Neoplasms
Maximum Tolerated Dose
Kidney
Thrombocytopenia
piritrexim
Neutropenia

Keywords

  • Antifolate
  • Antimetabolite
  • Cancer
  • Chemotherapy
  • Phase I

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase I study of piritrexim and gemcitabine in patients with advanced solid tumors. / Huie, Michael; Carducci, Michael A; Liu, Glenn; Wilding, George; Marnocha, Rebecca; Izquierda, Miguel; Thomas, James.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 28, No. 6, 12.2005, p. 613-617.

Research output: Contribution to journalArticle

Huie, Michael ; Carducci, Michael A ; Liu, Glenn ; Wilding, George ; Marnocha, Rebecca ; Izquierda, Miguel ; Thomas, James. / Phase I study of piritrexim and gemcitabine in patients with advanced solid tumors. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2005 ; Vol. 28, No. 6. pp. 613-617.
@article{d065f675c3cd42d2adfab2d35baec734,
title = "Phase I study of piritrexim and gemcitabine in patients with advanced solid tumors",
abstract = "Objectives: In this phase I study, the combination of piritrexim and gemcitabine was given to establish the maximum tolerated dose and the recommended phase II dose, and to determine a toxicity and efficacy profile. Methods: Fifty-two patients with normal and impaired renal function were enrolled on this phase I study. The starting dose was piritrexim 10 mg 3 times daily (5 days of the week for 3 weeks and 1 week off each 28-day cycle) and gemcitabine 1000 mg/m2 on days 1, 8, and 15. The piritrexim was escalated in a stepwise fashion with this dose of gemcitabine and then with gemcitabine 1000 mg/m2 for days 1 and 15. Results: The recommended phase II dose of this combination was felt to be piritrexim 50 mg/day (10 mg every morning, 20 mg every noon, and 20 mg every evening) with gemcitabine 1000 mg/m2 on days 1, 8, and 15, and piritrexim 75 mg/day (25 mg thrice daily) with gemcitabine 1000 mg/m2 on days 1 and 15. Neutropenia and thrombocytopenia were the most often reported toxicity. Dose-limiting toxicity was thrombocytopenia in both groups. The number of renal-impaired patients enrolled was too small to establish a maximum tolerated dose for this group (piritrexim became unavailable), but the combination was tolerated in the patients with impaired renal dysfunction. There was 1 complete response, 1 partial response, and 1 minimal response. Conclusion: The combination of piritrexim and gemcitabine was determined to be tolerable in heavily pretreated patients for use in solid tumors.",
keywords = "Antifolate, Antimetabolite, Cancer, Chemotherapy, Phase I",
author = "Michael Huie and Carducci, {Michael A} and Glenn Liu and George Wilding and Rebecca Marnocha and Miguel Izquierda and James Thomas",
year = "2005",
month = "12",
doi = "10.1097/01.coc.0000171281.13541.90",
language = "English (US)",
volume = "28",
pages = "613--617",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Phase I study of piritrexim and gemcitabine in patients with advanced solid tumors

AU - Huie, Michael

AU - Carducci, Michael A

AU - Liu, Glenn

AU - Wilding, George

AU - Marnocha, Rebecca

AU - Izquierda, Miguel

AU - Thomas, James

PY - 2005/12

Y1 - 2005/12

N2 - Objectives: In this phase I study, the combination of piritrexim and gemcitabine was given to establish the maximum tolerated dose and the recommended phase II dose, and to determine a toxicity and efficacy profile. Methods: Fifty-two patients with normal and impaired renal function were enrolled on this phase I study. The starting dose was piritrexim 10 mg 3 times daily (5 days of the week for 3 weeks and 1 week off each 28-day cycle) and gemcitabine 1000 mg/m2 on days 1, 8, and 15. The piritrexim was escalated in a stepwise fashion with this dose of gemcitabine and then with gemcitabine 1000 mg/m2 for days 1 and 15. Results: The recommended phase II dose of this combination was felt to be piritrexim 50 mg/day (10 mg every morning, 20 mg every noon, and 20 mg every evening) with gemcitabine 1000 mg/m2 on days 1, 8, and 15, and piritrexim 75 mg/day (25 mg thrice daily) with gemcitabine 1000 mg/m2 on days 1 and 15. Neutropenia and thrombocytopenia were the most often reported toxicity. Dose-limiting toxicity was thrombocytopenia in both groups. The number of renal-impaired patients enrolled was too small to establish a maximum tolerated dose for this group (piritrexim became unavailable), but the combination was tolerated in the patients with impaired renal dysfunction. There was 1 complete response, 1 partial response, and 1 minimal response. Conclusion: The combination of piritrexim and gemcitabine was determined to be tolerable in heavily pretreated patients for use in solid tumors.

AB - Objectives: In this phase I study, the combination of piritrexim and gemcitabine was given to establish the maximum tolerated dose and the recommended phase II dose, and to determine a toxicity and efficacy profile. Methods: Fifty-two patients with normal and impaired renal function were enrolled on this phase I study. The starting dose was piritrexim 10 mg 3 times daily (5 days of the week for 3 weeks and 1 week off each 28-day cycle) and gemcitabine 1000 mg/m2 on days 1, 8, and 15. The piritrexim was escalated in a stepwise fashion with this dose of gemcitabine and then with gemcitabine 1000 mg/m2 for days 1 and 15. Results: The recommended phase II dose of this combination was felt to be piritrexim 50 mg/day (10 mg every morning, 20 mg every noon, and 20 mg every evening) with gemcitabine 1000 mg/m2 on days 1, 8, and 15, and piritrexim 75 mg/day (25 mg thrice daily) with gemcitabine 1000 mg/m2 on days 1 and 15. Neutropenia and thrombocytopenia were the most often reported toxicity. Dose-limiting toxicity was thrombocytopenia in both groups. The number of renal-impaired patients enrolled was too small to establish a maximum tolerated dose for this group (piritrexim became unavailable), but the combination was tolerated in the patients with impaired renal dysfunction. There was 1 complete response, 1 partial response, and 1 minimal response. Conclusion: The combination of piritrexim and gemcitabine was determined to be tolerable in heavily pretreated patients for use in solid tumors.

KW - Antifolate

KW - Antimetabolite

KW - Cancer

KW - Chemotherapy

KW - Phase I

UR - http://www.scopus.com/inward/record.url?scp=29044440800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29044440800&partnerID=8YFLogxK

U2 - 10.1097/01.coc.0000171281.13541.90

DO - 10.1097/01.coc.0000171281.13541.90

M3 - Article

VL - 28

SP - 613

EP - 617

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 6

ER -